{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:48:23Z","timestamp":1786366103709,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10549-025-07661-2","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T01:19:31Z","timestamp":1740964771000},"page":"449-454","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Oncotype DX recurrence score in node-positive patients in the post-RxPONDER era: a single-institution experience"],"prefix":"10.1007","volume":"211","author":[{"given":"Rachel","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edi","family":"Brogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"El-Tamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah Y.","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"issue":"5","key":"7661_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/jnci\/dju055","volume":"106","author":"N Howlader","year":"2014","unstructured":"Howlader N, Altekruse SF, Li CI et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 106(5):55. https:\/\/doi.org\/10.1093\/jnci\/dju055","journal-title":"J Natl Cancer Inst"},{"key":"7661_CR2","unstructured":"Cancer Stat Facts: Female breast cancer subtypes. Accessed May 28, 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html"},{"issue":"23","key":"7661_CR3","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","volume":"24","author":"S Paik","year":"2006","unstructured":"Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 24(23):3726\u20133734. https:\/\/doi.org\/10.1200\/JCO.2005.04.7985","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"7661_CR4","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1200\/JCO.2007.15.1068","volume":"26","author":"JA Sparano","year":"2008","unstructured":"Sparano JA, Paik S (2008) Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol Off J Am Soc Clin Oncol 26(5):721\u2013728. https:\/\/doi.org\/10.1200\/JCO.2007.15.1068","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"7661_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF et al (2018) Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379(2):111\u2013121. https:\/\/doi.org\/10.1056\/NEJMoa1804710","journal-title":"N Engl J Med"},{"issue":"25","key":"7661_CR6","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR et al (2021) 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med 385(25):2336\u20132347. https:\/\/doi.org\/10.1056\/NEJMoa2108873","journal-title":"N Engl J Med"},{"issue":"16","key":"7661_CR7","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1200\/JCO.22.00069","volume":"40","author":"F Andre","year":"2022","unstructured":"Andre F, Ismaila N, Allison KH et al (2022) Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol Off J Am Soc Clin Oncol 40(16):1816\u20131837. https:\/\/doi.org\/10.1200\/JCO.22.00069","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"7661_CR8","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Breast Cancer V.2.2024."},{"issue":"12","key":"7661_CR9","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M et al (2020) Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J Clin Oncol Off J Am Soc Clin Oncol 38(12):1346\u20131366. https:\/\/doi.org\/10.1200\/JCO.19.02309","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"20","key":"7661_CR10","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update. J Clin Oncol Off J Am Soc Clin Oncol 36(20):2105\u20132122. https:\/\/doi.org\/10.1200\/JCO.2018.77.8738","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"7661_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387(1):9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690","journal-title":"N Engl J Med"},{"issue":"27","key":"7661_CR12","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817\u20132826. https:\/\/doi.org\/10.1056\/NEJMoa041588","journal-title":"N Engl J Med"},{"issue":"12","key":"7661_CR13","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1007\/s12325-015-0268-3","volume":"32","author":"SM Swain","year":"2015","unstructured":"Swain SM, Nunes R, Yoshizawa C, Rothney M, Sing AP (2015) Quantitative gene expression by recurrence score in ER-positive breast cancer, by age. Adv Ther 32(12):1222\u20131236. https:\/\/doi.org\/10.1007\/s12325-015-0268-3","journal-title":"Adv Ther"},{"issue":"10","key":"7661_CR14","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1245\/s10434-018-6598-z","volume":"25","author":"DM Bello","year":"2018","unstructured":"Bello DM, Russell C, McCullough D, Tierno M, Morrow M (2018) Lymph node status in breast cancer does not predict tumor biology. Ann Surg Oncol 25(10):2884\u20132889. https:\/\/doi.org\/10.1245\/s10434-018-6598-z","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"7661_CR15","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1055\/a-1111-8734","volume":"80","author":"VP Walter","year":"2020","unstructured":"Walter VP, Taran FA, Wallwiener M et al (2020) Distribution of the 21-gene breast recurrence score in patients with primary breast cancer in Germany. Geburtshilfe Frauenheilkd 80(6):619\u2013627. https:\/\/doi.org\/10.1055\/a-1111-8734","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"12","key":"7661_CR16","doi-asserted-by":"publisher","first-page":"7662","DOI":"10.1245\/s10434-022-12056-4","volume":"29","author":"MJ Amlicke","year":"2022","unstructured":"Amlicke MJ, Park J, Agala CB et al (2022) Prevalence of pathologic N2\/N3 disease in postmenopausal women with clinical N0 ER+\/HER2- breast cancer. Ann Surg Oncol 29(12):7662\u20137669. https:\/\/doi.org\/10.1245\/s10434-022-12056-4","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"7661_CR17","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s10549-011-1416-3","volume":"131","author":"KH Allison","year":"2012","unstructured":"Allison KH, Kandalaft PL, Sitlani CM, Dintzis SM, Gown AM (2012) Routine pathologic parameters can predict oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing? Breast Cancer Res Treat 131(2):413\u2013424. https:\/\/doi.org\/10.1007\/s10549-011-1416-3","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"7661_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10549-021-06443-w","volume":"191","author":"KR Pawloski","year":"2022","unstructured":"Pawloski KR, Gonen M, Wen HY et al (2022) Supervised machine learning model to predict oncotype DX risk category in patients over age 50. Breast Cancer Res Treat 191(2):423\u2013430. https:\/\/doi.org\/10.1007\/s10549-021-06443-w","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"7661_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10549-017-4619-4","volume":"168","author":"K Singh","year":"2018","unstructured":"Singh K, He X, Kalife ET, Ehdaivand S, Wang Y, Sung CJ (2018) Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results. Breast Cancer Res Treat 168(1):29\u201334. https:\/\/doi.org\/10.1007\/s10549-017-4619-4","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"7661_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10549-017-4170-3","volume":"163","author":"A Orucevic","year":"2017","unstructured":"Orucevic A, Bell JL, McNabb AP, Heidel RE (2017) Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data. Breast Cancer Res Treat 163(1):51\u201361. https:\/\/doi.org\/10.1007\/s10549-017-4170-3","journal-title":"Breast Cancer Res Treat"},{"issue":"17","key":"7661_CR21","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.3390\/cancers15174264","volume":"15","author":"AM Roy","year":"2023","unstructured":"Roy AM, Jiang C, Perimbeti S, Deng L, Shapiro CL, Gandhi S (2023) Oncotype Dx score, HER2 low expression, and clinical outcomes in early-stage breast cancer: a national cancer database analysis. Cancers 15(17):4264. https:\/\/doi.org\/10.3390\/cancers15174264","journal-title":"Cancers"},{"key":"7661_CR22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.breast.2021.08.016","volume":"60","author":"R Mutai","year":"2021","unstructured":"Mutai R, Barkan T, Moore A et al (2021) Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer. The Breast 60:62\u201369. https:\/\/doi.org\/10.1016\/j.breast.2021.08.016","journal-title":"The Breast"},{"issue":"3","key":"7661_CR23","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10549-018-4796-9","volume":"170","author":"V Sopik","year":"2018","unstructured":"Sopik V, Narod SA (2018) The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. Breast Cancer Res Treat 170(3):647\u2013656. https:\/\/doi.org\/10.1007\/s10549-018-4796-9","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"7661_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4048\/jbc.2021.24.e4","volume":"24","author":"SK Min","year":"2021","unstructured":"Min SK, Lee SK, Woo J et al (2021) Relation between tumor size and lymph node metastasis according to subtypes of breast cancer. J Breast Cancer 24(1):75\u201384. https:\/\/doi.org\/10.4048\/jbc.2021.24.e4","journal-title":"J Breast Cancer"},{"issue":"11","key":"7661_CR25","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1111\/j.1445-2197.2006.03918.x","volume":"76","author":"S Laura","year":"2006","unstructured":"Laura S, Coombs NJ, Ung O, Boyages J (2006) Tumour size as a predictor of axillary node metastases in patients with breast cancer. ANZ J Surg 76(11):1002\u20131006. https:\/\/doi.org\/10.1111\/j.1445-2197.2006.03918.x","journal-title":"ANZ J Surg"},{"issue":"6","key":"7661_CR26","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00268-001-0003-x","volume":"25","author":"MJ Silverstein","year":"2001","unstructured":"Silverstein MJ, Skinner KA, Lomis TJ (2001) Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World J Surg 25(6):767\u2013772. https:\/\/doi.org\/10.1007\/s00268-001-0003-x","journal-title":"World J Surg"},{"issue":"1","key":"7661_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10549-021-06365-7","volume":"190","author":"LL de Moura","year":"2021","unstructured":"de Moura LL, Cesca MG, Tavares MC et al (2021) HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer. Breast Cancer Res Treat 190(1):155\u2013163. https:\/\/doi.org\/10.1007\/s10549-021-06365-7","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"7661_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","volume":"7","author":"F Schettini","year":"2021","unstructured":"Schettini F, Chic N, Bras\u00f3-Maristany F et al (2021) Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer 7(1):1. https:\/\/doi.org\/10.1038\/s41523-020-00208-2","journal-title":"NPJ Breast Cancer"},{"issue":"8","key":"7661_CR29","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","volume":"22","author":"C Denkert","year":"2021","unstructured":"Denkert C, Seither F, Schneeweiss A et al (2021) Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol 22(8):1151\u20131161. https:\/\/doi.org\/10.1016\/S1470-2045(21)00301-6","journal-title":"Lancet Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07661-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07661-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07661-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T03:16:13Z","timestamp":1744859773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07661-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["7661"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07661-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"14 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}